体外心室辅助治疗心源性休克的临床应用现况

李平; 徐博翎; 吴婷婷; 董念国

doi:10.13201/j.issn.1001-1439.2021.06.002

体外心室辅助治疗心源性休克的临床应用现况

- 1. 华中科技大学同济医学院附属协和医院心脏大血管外科(武汉,430022);
- 2. 苏州大学机电工程学院人工器官研究所

详细信息

通讯作者: 董念国,E-mail:dongnianguo@hotmail.com

中图分类号: R654.2

收稿日期: 2021-02-22

Extracorporeal ventricular assist device for acute cardiogenic shock: a review

- 1. Department of Cardiovascular Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology, Wuhan, 430022, China;
- 2. Artificial Organ Technology Lab,Soochow University,School of Mechanical and Electrical Engineering

More Information

Corresponding author: DONG Nianguo, E-mail: dongnianguo@hotmail.com

Received Date: 22 February 2021

摘要

摘要: 心源性休克常发于终末期心力衰竭(心衰)急性恶化以及急性心肌梗死患者,是由于各种原因导致的心脏泵功能严重衰退,造成血流动力学急剧不稳、重要器官灌注严重不足的临床综合征,是心衰患者死亡的重要原因。在最佳药物治疗和行冠状动脉(冠脉)血管再通术等非药物治疗措施无效后,这类患者可以使用短期机械循环辅助系统,借此维持血流动力学稳定,保证脏器有效灌注,改善心功能和降低心脏负荷。本文综述了外周机械循环辅助以及外科体外心室辅助治疗心源性休克的临床应用现状。依据本文临床数据分析结果,外科体外心室辅助装置在心源性休克病症治疗的应用中具有生存率高、并发症种类少且发生率低、支持时间长等明显优势,在合适的患者群体中可能具有更好的治疗效果,且有望更加适合于我国国情下的急性心衰治疗和移植前过渡支持。
- 心室辅助装置 /
- 心源性休克 /
- 机械循环辅助
Abstract: Cardiogenic shock(CS) often occurs in patients suffering from rapid progression of end-stage heart failure or acute myocardial infarction. It is a state of circulatory failure due to insufficient cardiac output. CS can lead to severe ischemia, hypoxia, metabolic impairment and multi-organ failure and remain the major cause of death in heart failure patients. Mechanical circulatory support may be used for patients, who do not response to optimal medication or revascularization, to stabilize hemodynamics, recover organ perfusion, improve the cardiac function, and unload the failing ventricle. This paper reviews the clinical use of percutaneous mechanical circulatory support devices and surgical extracorporeal ventricular assist devices(Extra-VADs) on cardiogenic shock patients. Extra-VADs have the advantage of high survival rate, less complications, capability for extended support duration. Extra-VADs hold good potential in well-selected patient group and can be promising for acute heart failure treatment and bridge to transplant support in China.
- ventricular assist device /
- cardiogenic shock /
- mechanical circulatory support

HTML全文

参考文献(43)

[1]	中华医学会心血管病学分会,心血管急重症学,中华心血管病杂志编辑委员会.心原性休克诊断和治疗中国专家共识[J].中华心血管病杂志,2019,47(4):265-277.
[2]	Jentzer JC,van Diepen S,Barsness GW,et al.Cardiogenic shock classification to predict mortality in the cardiac intensive care unit[J].J Am Coll Cardiol,2019,74(17):2117-2128.
[3]	den Uil CA,Akin S,Jewbali LS,et al.Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock:a systematic review and meta-analysis[J].Eur J Cardiothorac Surg,2017,52(1):14-25.
[4]	Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC).Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2016,18(8):891-975.
[5]	Massey HT,Choi JH,Maynes EJ,et al.Temporary support strategies for cardiogenic shock:extracorporeal membrane oxygenation,percutaneous ventricular assist devices and surgically placed extracorporeal ventricular assist devices[J].Ann Cardiothorac Surg,2019,8(1):32-43.
[6]	Combes A,Price S,Slutsky AS,et al.Temporary circulatory support for cardiogenic shock[J].Lancet,2020,396(10245):199-212.
[7]	Thiele H,Ohman EM,de Waha-Thiele S,et al.Management of cardiogenic shock complicating myocardial infarction:an update 2019[J].Eur Heart J,2019,40(32):2671-2683.
[8]	Sef D,Mohite P,De Robertis F,et al.Bridge to heart transplantation using the Levitronix CentriMag short-term ventricular assist device[J].Artif Organs,2020,44(9):1006-1008.
[9]	Thiele H,Schuler G,Neumann FJ,et al.Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock:design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II(IABP-SHOCK II)trial[J].Am Heart J,2012,163(6):938-945.
[10]	Virani SS,Alonso A,Benjamin EJ,et al.Heart Disease and Stroke Statistics-2020 Update:A Report From the American Heart Association[J].Circulation,2020,141(9):e139-e596.
[11]	Seyfarth M,Sibbing D,Bauer I,et al.A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction[J].J Am Coll Cardiol,2008,52(19):1584-1588.
[12]	Hendrickson WA,Ward KB.Atomic models for the polypeptide backbones of myohemerythrin and hemerythrin[J].Biochem Biophys Res Commun,1975,66(4):1349-1356.
[13]	Burkhoff D,Cohen H,Brunckhorst C,et al.A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock[J].Am Heart J,2006,152(3):469.e1-8.
[14]	Xie A,Phan K,Tsai YC,et al.Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest:a meta-analysis[J].J Cardiothorac Vasc Anesth,2015,29(3):637-645.
[15]	Cheng R,Hachamovitch R,Kittleson M,et al.Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest:a meta-analysis of 1,866 adult patients[J].Ann Thorac Surg,2014,97(2):610-616.
[16]	Koerner MM,Harper MD,Gordon CK,et al.Adult cardiac veno-arterial extracorporeal life support(VA-ECMO):prevention and management of acute complications[J].Ann Cardiothorac Surg,2019,8(1):66-75.
[17]	AL Hanshi SAM,AL Othmani F.A case study of Harlequin syndrome in VA-ECMO[J].Qatar Med J,2017:39.
[18]	Williams B,Bernstein W.Review of venoarterial extracorporeal membrane oxygenation and development of intracardiac thrombosis in adult cardiothoracic patients[J].J Extra Corpor Technol,2016,48(4):162-167.
[19]	Weber C,Deppe AC,Sabashnikov A,et al.Left ventricular thrombus formation in patients undergoing femoral veno-arterial extracorporeal membrane oxygenation[J].Perfusion,2018,33(4):283-288.
[20]	Cevasco M,Takayama H,Ando M,et al.Left ventricular distension and venting strategies for patients on venoarterial extracorporeal membrane oxygenation[J].J Thorac Dis,2019,11(4):1676-1683.
[21]	Schrage B,Becher PM,Bernhardt A,et al.Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation:results from an international,multicenter cohort study[J].Circulation,2020,142(22):2095-2106.
[22]	Donker DW,Brodie D,Henriques J,et al.Left ventricular unloading during veno-arterial ECMO:a simulation study[J].ASAIO J,2019,65(1):11-20.
[23]	De Robertis F,Birks EJ,Rogers P,et al.Clinical performance with the Levitronix Centrimag short-term ventricular assist device[J].J Heart Lung Transplant,2006,25(2):181-186.
[24]	Takeda K,Garan AR,Ando M,et al.Minimally invasive CentriMag ventricular assist device support integrated with extracorporeal membrane oxygenation in cardiogenic shock patients:a comparison with conventional CentriMag biventricular support configuration[J].Eur J Cardiothorac Surg,2017,52(6):1055-1061.
[25]	Takayama H,Chen JM,Jorde UP,et al.Implantation technique of the CentriMag biventricular assist device allowing ambulatory rehabilitation[J].Interact Cardiovasc Thorac Surg,2011,12(2):110-111.
[26]	Barbone A,Malvindi PG,Sorabella RA,et al.6 months of "temporary" support by Levitronix left ventricular assist device[J].Artif Organs,2012,36(7):639-642.
[27]	Borisenko O,Wylie G,Payne J,et al.Thoratec CentriMag for temporary treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency:a systematic literature review and meta-analysis of observational studies[J].ASAIO J,2014,60(5):487-497.
[28]	Truby L,Mundy L,Kalesan B,et al.Contemporary outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock at a large tertiary care center[J].ASAIO J,2015,61(4):403-409.
[29]	Flécher E,Anselmi A,Corbineau H,et al.Current aspects of extracorporeal membrane oxygenation in a tertiary referral centre:determinants of survival at follow-up[J].Eur J Cardiothorac Surg,2014,46(4):665-671.
[30]	Vallabhajosyula S,O'Horo JC,Antharam P,et al.Venoarterial extracorporeal membrane oxygenation with concomitant impella versus venoarterial extracorporeal membrane oxygenation for cardiogenic shock[J].ASAIO J,2020,66(5):497-503.
[31]	Capoccia M,Avtaar Singh S,Hegazy Y,et al.Rescue Levitronix Centrimag as a bridge to decision:is it still worthwhile?[J].Indian J Thorac Cardiovasc Surg,2017,33(4):303-308.
[32]	Moonsamy P,Axtell AL,Ibrahim NE,et al.Survival after heart transplantation in patients bridged with mechanical circulatory support[J].J Am Coll Cardiol,2020,75(23):2892-2905.
[33]	Hei F,Lou S,Li J,et al.Five-year results of 121 consecutive patients treated with extracorporeal membrane oxygenation at Fu Wai Hospital[J].Artif Organs,2011,35(6):572-578.
[34]	Chung M,Cabezas FR,Nunez JI,et al.Hemocompatibility-related adverse events and survival on venoarterial extracorporeal life support:An ELSO registry analysis[J].JACC Heart Fail,2020,8(11):892-902.
[35]	Smedira NG,Moazami N,Golding CM,et al.Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure:survival at five years[J].J Thorac Cardiovasc Surg,2001,122(1):92-102.
[36]	Rastan AJ,Dege A,Mohr M,et al.Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock[J].J Thorac Cardiovasc Surg,2010,139(2):302-311,311.e1.
[37]	Lemor A,Hosseini Dehkordi SH,Basir MB,et al.Impella Versus extracorporeal membrane oxygenation for acute myocardial infarction cardiogenic shock[J].Cardiovasc Revasc Med,2020,21(12):1465-1471.
[38]	Pozzi M,Banfi C,Grinberg D,et al.Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock due to myocarditis in adult patients[J].J Thorac Dis,2016,8(7):E495-502.
[39]	Mohite PN,Sabashnikov A,Patil NP,et al.Short-term ventricular assist device in post-cardiotomy cardiogenic shock:factors influencing survival[J].J Artif Organs,2014,17(3):228-235.
[40]	Takayama H,Truby L,Takeda K,et al.Short-term ventricular assist devices(implantable and percutaneous)[J].Curr Surg Rep,2014,2(6):58.
[41]	Loforte A,Marinelli G,Musumeci F,et al.Extracorporeal membrane oxygenation support in refractory cardiogenic shock:treatment strategies and analysis of risk factors[J].Artif Organs,2014,38(7):E129-141.
[42]	John R,Long JW,Massey HT,et al.Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support[J].J Thorac Cardiovasc Surg,2011,141(4):932-939.
[43]	Sung SY,Hsu PS,Chen JL,et al.Prolonged use of levitronix left ventricular assist device as a bridge to heart transplantation[J].Acta Cardiol Sin,2015,31(3):249-252.